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Abstract: Although β-blockers have been previously shown to effectively reduce blood 
pressure (BP) and have been used for hypertension treatment for over 40 years, their effect 
on cardiovascular morbidity and mortality in hypertensive patients remains controversial and 
its use in uncomplicated hypertension is currently under debate. However, data on the above 
ﬁ  eld derive mainly from studies which were conducted with older agents, such as atenolol and 
metoprolol, while considerable pharamacokinetic and pharmacodynamic heterogeneity is pres-
ent within the class of β-blockers. Carvedilol, a vasodilating non-cardioselective β-blocker, is 
a compound that seems to give the opportunity to the clinician to use a cardioprotective agent 
without the concerning hemodynamic and metabolic actions of traditional β-blocker therapy. In 
contrast with conventional β-blockers, carvedilol maintains cardiac output, has a less extended 
effect on heart rate and reduces BP by decreasing vascular resistance. Further, several studies 
has shown that carvedilol has a beneﬁ  cial or at least neutral effect on metabolic parameters, 
such as glycemic control, insulin sensitivity, and lipid metabolism, suggesting that they could 
be used in subjects with the metabolic syndrome or diabetes without negative consequences. 
This article summarizes the distinct pharmacologic, hemodynamic, and metabolic properties 
of carvedilol in relation to conventional β-blockers, attempting to examine the potential use of 
this agent for hypertension treatment.
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Introduction
Hypertension represents the most common cardiovascular risk factor. Its prevalence 
is continuously rising, affecting more than 25% of the adult population in developed 
societies (Wolf-Maier et al 2004; Saraﬁ  dis et al 2004; Saraﬁ  dis and Bakris 2008). 
On the other hand, several previous studies have clearly shown longitudinal asso-
ciations between hypertension and coronary artery disease, myocardial infarction, 
stroke, congestive heart failure, and peripheral vascular disease (MacMahon et al 
1990; Stamler et al 1993) and lowering blood pressure (BP) signiﬁ  cantly reduces the 
cardiovascular morbidity and mortality (Collins et al 1990; MacMahon et al 1997). 
However, control rates of hypertension is currently inappropriate and the majority 
of the hypertensive patients will require two or more antihypertensive agents to 
reach target BP goals (Chobanian et al 2003; ESH-ESC Guidelines Committee 2003; 
Mancia et al 2007).
Beta-blockers have been used for more than 40 years to treat hypertension (Saraﬁ  dis 
and Bakris 2006b). Data from clinical trials that used these agents to manage BP have 
demonstrated reductions in cardiovascular mortality and this has resulted in recommen-
dations of β-blockers as ﬁ  rst- or second-line antihypertensive agents in the most recent 
guidelines of the European Society of Hypertension/European Society of Cardiology 
(Mancia et al 2007) and the Joint National Committee (JNC 7) on the Prevention, Detec-
tion and Treatment of High Blood Pressure (Chobanian et al 2003). All of the β-blocker 
compounds now available for use have been approved for the treatment of hypertension Vascular Health and Risk Management 2008:4(1) 24
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(Opie and Yusuf 2005). Despite the above and the wide use 
of β-blockers for the management of hypertension, their use 
in patients with uncomplicated hypertension has become 
increasingly controversial over the past few years (Saraﬁ  dis 
and Bakris 2006c; Black and Sica 2007). This was in part due 
to the results of recent meta-analyses showing no difference 
between atenolol and placebo in risk reduction for mortality, 
myocardial infarction, or stroke (Carlberg et al 2004) and an 
increased risk of mortality and stroke with atenolol or pro-
pranolol in comparison to other antihypertensive drug classes, 
including diuretics, angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARBs), and calcium-
channel blockers (CCBs) (Carlberg et al 2004; Lindholm et al 
2005). The recently updated National Institute for Health and 
Clinical Excellence guidelines in Great Britain reﬂ  ected this 
concern, having changed the indication for β-blockers from use 
as ﬁ  rst-line agents for hypertension treatment to consideration 
as a fourth-line add-on therapy in patients requiring multiple 
drugs (Williams et al 2004; National Collaborating Centre 
for Chronic Conditions 2006). In the most recent guidelines, 
the European Society of Hypertension / European Society of 
Cardiology (Mancia et al 2007) recommend that β-blockers 
should not be preferred in hypertensives with multiple meta-
bolic risk factors including metabolic syndrome, abdominal 
obesity, high normal or impaired fasting glucose, and impaired 
glucose tolerance, conditions that make the risk of incident 
diabetes higher.
Although the above data on β-blockers and CVD risk 
reduction cannot be overlooked, one must always bear 
in mind that most of the studies on the field included 
“traditional” agents (such as propranolol and atenolol). 
This notion is of great importance, since, although a class 
effect is possible for certain facets of β-blocker action, many 
effects of the various β-blockers differ greatly between the 
various compounds, according to the individual physico-
chemical and pharmacological properties of each of them 
(Williams et al 2004). Several head-to-head studies have 
convincingly shown that non-selective agents, such as 
atenolol, have a negative effect on myocardial contractility, 
vascular resistance (Man et al 1988), and carbohydrate and 
lipid metabolism (Saraﬁ  dis and Bakris 2007), while newer 
agents with vasodilating properties, such as carvedilol and 
nebivolol, have a hemodynamic and metabolic proﬁ  le that 
is much better than that of older compounds (Saraﬁ  dis and 
Bakris 2006b; Weiss 2006; Sica 2007). The present review 
summarizes the current data on the pharmacologic, hemody-
namic, and metabolic properties of carvedilol in comparison 
with conventional β-blocking compounds, in an attempt to 
examine whether this particular agent could be still useful 
in the treatment of hypertension.
Pharmacologic properties
of β-blockers
First generation β-blockers, such as propranolol, block both 
β1- and β2-receptors. Through β1-receptor blocking these 
compounds induce the well known inhibitory effects on 
the function of the sinus and atrioventricular nodes and on 
myocardial contraction (negative chronotropic, dromotropic, 
and inotropic effect). By blocking the β2-receptors, they cause 
contraction of smooth muscle with a risk of bronchospasm 
in predisposed individuals (Kaplan 2005b; Opie and Yusuf 
2005). Second-generation agents, such as atenolol, metopro-
lol, and others, have relative low selectivity when given in low 
doses for the β1-receptors and they are preferable in patients 
with chronic lung disease or in chronic smokers. Finally, 
third-generation agents such as labetalol and carvedilol have 
additional vasodilatory properties due to α-adrenergic block-
ade capacity (Table 1) (Frishman 1998; Sica 2007). Even in 
small doses, β-blockers begin to lower BP within a few hours 
(Kaplan 2005b). The plasma half-live of the various β-blockers 
range from just 9 minutes for esmolol to 24 hours for nadolol 
and penbutolol (median half-live of the class about 6 hours), 
but the effective half-life is longer mainly because of the active 
metabolites. Longer-acting compounds such as nadolol and 
extended-release formulations such as slow-release proprano-
lol or extended-release metoprolol increase the probability of 
medication adherence and should be preferred for treatment 
of hypertension (Opie and Yusuf 2005).
Carvedilol is a third-generation, vasodilating noncardi-
oselective β-blocker which lacks intrinsic sympathomimetic 
activity (ISA). In addition to its β-blocking effects, it has 
blocking effects at vascular α1-receptors, antioxidant, and 
calcium antagonist properties (Opie and Yusuf 2005). Experi-
mental models demonstrate that carvedilol blocks α1-, β1-, 
and β2- adrenergic receptors (McTavish et al 1993) without 
exhibiting high levels of inverse agonist activity. The lack 
of inverse agonist activity and ISA reduces the side-effects 
and makes the compound better tolerated than the older 
β-blockers (Yoshikawa et al 1996).
Carvedilol is rapidly absorbed after an oral dose, reaching 
peak plasma drug concentrations within 1 to 2 hours. Absorp-
tion is delayed an additional 1 to 2 hours when the drug is 
administered with food (Morgan 1994). The plasma half-life 
of carvedilol ranges from 7 to 10 hours in most subjects; thus, 
the drug requires twice-daily dosing. In plasma, 98% of the 
drug is bound to plasma proteins, predominantly to albumin Vascular Health and Risk Management 2008:4(1) 25
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(Morgan 1994). Carvedilol is almost exclusively metabo-
lized by the liver and its metabolism is affected by genetic 
polymorphism of cytochrome P-450 2D6 activity. Drugs that 
inhibit cytochrome P-450 2D6 activity, such as quinidine, 
paroxetine, ﬂ  uoxetine, and propafenone, may also increase 
plasma carvedilol concentrations. Thus, patients taking these 
drugs may be at particularly high risk of hypotension due to 
excessive α-adrenoreceptor blockade. Clearance of carve-
dilol is delayed in patients over 65 years of age. On average, 
their plasma carvedilol concentrations are 50% higher than 
in younger patients (Frishman 1998). The pharmacokinetics 
of carvedilol are signiﬁ  cantly altered in patients with liver 
disease but not so in the presence of renal failure (Neugebauer 
et al 1992; Kramer et al 1992; Frishman 1998). Less than 2% 
of the parent drug recovers in the urine (Frishman 1998). 
Some of the metabolites of carvedilol have β-adrenoreceptor-
antagonist activity, and one 4-hydroxyphenyl metabolite is 
approximately 13 times as potent as carvedilol in this regard. 
Approximately 60% of these metabolites are secreted with 
bile and excreted with the faeces (Frishman 1998).
Hemodynamic effects of carvedilol
Essential hypertension is a disease with complex aetiol-
ogy and various factors are implicated in its pathogenesis. 
In terms of the circulation, elevations in BP can be the result 
of either an increase in cardiac output or a rise in peripheral 
vascular resistance (Kaplan 2005a). The development of 
the essential hypertension is usually slow and gradual and 
regardless of the triggering mechanism, eventually increased 
peripheral vascular resistance becomes the main hemody-
namic fault (Lever and Harrap 1992).
Most antihypertensive agents act through a decrease in 
vascular resistance while sparing cardiac output, but traditional 
β-blockers are an exception to this rule. The most common 
ways by which non-vasodilating β-blockers reduce BP include 
a decrease in cardiac output, sympathetic outﬂ  ow, and, prob-
ably, renin release while systemic vascular resistance remains 
unchanged or even increases (Messerli and Grossman 2004; 
Black and Sica 2007). In contrast, carvedilol seems to lower BP 
by decreasing peripheral vascular resistance, without affecting 
cardiac output; due to the α1-adrenergic blocking effect, which 
accounts for its vasodilatory effects, the hemodynamic effect 
of carvedilol is similar to those of ACE inhibitors and CCBs 
(Frishman 1998) and it can be expected to have a more consis-
tent BP-lowering effect than do traditional β-blockers, such as 
atenolol or metoprolol (Messerli and Grossman 2004).
Hypertension is associated with the development of left 
ventricular hypertrophy (LVH) and LVH is strongly related to 
Table 1 Pharmacologic properties of β-blockers
Generic name  β1-  α-  ISA  Lipid   Loss by liver or   Plasma  Plasma protein 
  selective  blocker    solubility  kidney  Half-life (h)  binding (%)
Noncardioselective          
 Propranolol  –  –  –  +++  Liver  1–6  90
 Carteolol  –  –  +  0/+  Kidney  5–6  20–30
 Nadolol  –  –  –  0  Kidney  20–24  30
 Penbutolol  –  –  +  +++  Liver  20–25  98
 Sotalol  –  –  –  0  Kidney  7–18  5
 Timolol  –  –  –  +  Liver,  kidney  4–5  60
Cardioselective            
 Acebutolol  +  –  ++  0  Liver,  kidney  8–13  15
 Atenolol  +  –  –  0  Kidney  6–7  10
 Betaxolol  +  –  –  ++  Liver  then  kidney  14–22  50
 Bisoprolol  +  –  –  +  Liver,  kidney  9–12  30
 Metoprolol  +  –  –  +  Liver  3–7  12
Vasodilatory β-blockers
nonselective    
 Labetalol  –  +  –  +++  Liver,  some  kidney  6–8  90
 Pindolol  –  +  +++  +  Liver,  kidney  4  55
 Carvedilol  –  +  –  +  Liver  6  95
Vasodilatory β-blockers,
cardioselective    
  Celiprolol  +  +  +  0/+  Kidney, then liver  6–8  –
 Nebivolol  +  –  –  +  Liver  10–30a 98
Modiﬁ  ed from Opie and Yusuf (2005).
aKuroedov (2004).
Abbreviation: ISA, intrinsic sympathomimetic activity.Vascular Health and Risk Management 2008:4(1) 26
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subsequent cardiovascular morbidity and mortality (Messerli 
et al 1993; Benjamin and Levy 1999). All antihypertensive 
agents have been shown to cause regression of LVH , but 
β-blockers seem to be less effective to this end (Fleischmann 
and Schmieder 2002; Verdecchia et al 2004; Gosse 2005). 
Schulman et al (1990) reported that atenolol failed to 
reduce LVH in the elderly when compared with verapamil. 
In the Losartan Intervention for End-Point Reduction in 
Hypertension (LIFE) study (Dahlof et al 2002), losartan was 
more efﬁ  cacious than atenolol in LVH reduction. Although 
Galzerano et al (2005) reported a superior left ventricular 
mass regression with telmisartan versus carvedilol, the latter 
may have a more beneﬁ  cial effect on LVH compared with 
the conventional β-blockers, due to its vasodilating properties 
(Messerli and Grossman 2004); however no double-blind 
study comparing carvedilol with traditional β-blockers in 
patients with LVH is currently available.
Effects of carvedilol on insulin 
sensitivity and glycemic control
For more than 20 years one of the hottest research topics in the 
ﬁ  eld of hypertension therapeutics was the actions of the various 
agents used for hypertension treatment on parameters related 
to carbohydrate metabolism (Saraﬁ  dis and Bakris 2006a). 
A considerable number of clinical studies have examined 
the effects of the various antihypertensive classes on insulin 
sensitivity (IS), glycemic control, and incidence of diabetes 
mellitus. The broad conclusion is that thiazide diuretics and 
β-blockers deteriorate IS and thus increase the propensity of 
hypertensive patients to new-onset diabetes, whereas ACE-
inhibitors, CCBs and ARBs have rather neutral or beneﬁ  cial 
effects on these parameters (Saraﬁ  dis and Bakris 2006b, d).
However, accumulating evidence suggests that with 
regard to β-blockers an important exception apply to the 
above general “rule”; newer, vasodilating, agents seem to 
have a much different metabolic proﬁ  le than older ones 
(Saraﬁ  dis and Bakris 2006d). Previous studies using the 
euglycemic hyperinsulinemic clamp technique have shown 
that treatment of hypertensive patients with conventional 
β-blockers, either nonselective, like propranolol (Lithell 
et al 1992), or β1-selective, like atenolol (Pollare et al 1989a; 
Pollare et al 1989b) or metoprolol (Pollare et al 1989b), 
decreases IS by about 15%–35%. In addition, in the LIFE 
study (Dahlof et al 2002), patients who received atenolol 
experienced a 25% greater risk of new-onset diabetes com-
pared with those who received losartan.
In contrast, some studies suggest that newer β-blockers 
with vasodilating properties can have beneﬁ  cial effects on 
parameters as glycemic control and insulin sensitivity (Haenni 
and Lithell 1994; Malminiemi 1995). Jacob et al have previ-
ously compared the effects of carvedilol and metoprolol in 
72 hypertensive patients and observed a 14% increase in IS 
estimated with the clamp with carvedilol afterwards, whereas 
metoprolol was associated with a reduction in this parameter 
(Haenni and Lithell 1994; Jacob et al 1996). In another study 
of the ﬁ  eld, Giuglano et al investigated the effects of carve-
dilol and atenolol in 45 patients with both hypertension and 
type 2 diabetes. After 24 weeks of treatment, fasting plasma 
glucose and HbA1c were decreased and IS measured with 
the clamp was increased with carvedilol, whereas ateno-
lol had the opposite results (Giugliano et al 1997). In the 
Carvedilol or Metoprolol European Trial (COMET) study 
(Poole-Wilson et al 2003), the risk for new-onset diabetes 
was 22% lower in patients receiving carvedilol than those 
receiving metoprolol. In addition, the Glycemic Effects in 
Diabetes Mellitus: Carvedilol-Metoprolol Comparison in 
Hypertensives (GEMINI) multi-center trial (Bakris et al 
2004), that compared carvedilol with metoprolol treatment in 
1235 subjects with hypertension and type 2 diabetes showed 
a signiﬁ  cant decrease in the HOMA-IR index of about 9% 
with carvedilol. These ﬁ  ndings clearly support a less detri-
mental effect of vasodilating compared with older β-blockers 
on glycemic control and insulin sensitivity and suggest that 
among the class of β-blockers, the former agents should be 
preferred in subjects with components of the metabolic syn-
drome, impaired glucose tolerance or type 2 diabetes.
Effects of carvedilol on lipid 
metabolism
Several studies have shown that β-blockers increase triglycer-
ide levels and decrease high-density lipoprotein (HDL) levels 
(Kasiske et al 1995; Brook 2000; Maitland-van der Zee et al 
2001). Cardioselective β-blockers with ISA have a lesser effect 
on triglycerides and HDL levels than non-cardioselective 
β-blockers without ISA ( Pollare et al 1989b; Roberts 1989; 
Kasiske et al 1995). In a review of 474 studies, Kasiske et al 
showed also that long-term treatment with β-blockers reduces 
the effect on HDL levels (Kasiske et al 1995).
In contrast to older β-blockers, carvedilol seems to have 
a neutral or beneﬁ  cial effect on lipoprotein lipase activity 
and levels of triglycerides and HDL (Giugliano et al 1997; 
Bakris et al 2004). In 45 patients with non-insulin-dependent 
diabetes and hypertension who were treated for 24 weeks, 
patients receiving carvedilol had a more favorable effect 
compared with atenolol in lowering triglyceride levels, 
increasing HDL levels, and decreasing lipid peroxidation Vascular Health and Risk Management 2008:4(1) 27
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(Giugliano et al 1997). These beneﬁ  cial effects of carvedilol 
on lipid levels is another important advantage of this agent 
in comparison to the conventional compounds.
Hypertension-induced nephropathy
Hypertension is a well-established risk factor for chronic 
kidney disease (Saraﬁ  dis et al 2007) and hypertensive renal 
disease is the second major cause of end-stage renal disease 
in the developed societies (US Renal Data System 2005). 
Microalbuminuria, which can be found in many hyperten-
sive patients, is considered today a marker of abnormal 
vascular function and a risk factor of cardiovascular dis-
ease, while elevation of urine albumin excretion at levels of 
macroalbuminuria is considered as a typical sign of overt 
nephropathy and is directly associated with the rate of renal 
function decline (Saraﬁ  dis and Bakris 2006e). As hyperten-
sion-induced nephrosclerosis proceeds, renal blood ﬂ  ow and 
glomerular ﬁ  ltration rate decrease, and ﬁ  ltration fraction 
increases long before plasma creatinine level begins to rise. 
Non-vasodilating β-blockers further decrease renal blood 
ﬂ  ow and increase ﬁ  ltration fraction. In addition, although 
short-term therapy with β-blockers decreases microalbu-
minuria, long-term therapy fails to reduce microalbuminuria 
compared with ACE inhibitors or nondihydropyridine CCB, 
despite equal antihypertensive efﬁ  cacy (Hannedouche et al 
1994) and there is general no evidence that conventional 
β-blockers possess renoprotective properties.
In contrast to traditional β-blockers, several trials have 
demonstrated a beneﬁ  cial effect of carvedilol on kidney 
function including an increase in renal blood ﬂ  ow and a 
reduction in microalbuminuria (Dupont et al 1987; Dupont 
1990; Marchi and Ciriello 1995; Agrawal et al 1996). In 
addition, in GEMINI trial (Bakris et al 2004), among patients 
with normal urine albumin excretion in baseline, fewer 
progressed to microalbuminuria in the carvedilol than in 
the metoprolol group (6.4% vs 10.3% respectively). These 
ﬁ  ndings support a possible beneﬁ  cial effect of carvedilol on 
renal function and call for a prospective trial examining the 
effect of this drug on hard renal end-points (ie, incidence 
of end-stage renal disease) in patients with chronic kidney 
disease and proteinuria.
Elderly patients
The Swedish Trial in Old Patients with Hypertension 
(STOP-Hypertension) (Dahlof et al 1991) found a signiﬁ  -
cant reduction in the incidence of stroke and cardiovascular 
mortality by β-blockade (atenolol, metoprolol, or pindolol 
usually combined with diuretics) but just a marginal reduction 
in the incidence of myocardial infarction. In the elderly, 
aging is accompanied by a progressive decrease in cardio-
vascular responsiveness to β-adrenergic stimulation and by 
an increase in plasma catecholamine levels, similar to the 
effects observed with pharmacologic β-blockade (Messerli 
and Grossman 2004). Fleg et al (1994) showed that the age-
associated decreases in maximal heart rate and left ventricular 
contractility with exercise are probably manifestations of 
a reduced β-adrenergic responsiveness and thus adding 
β-blockers may result in poor tolerability in elderly patients. 
The α-blocking effect of carvedilol may counterbalance some 
of the negative chronotropic and inotropic effects associated 
with older β-blockers and may have a more favorable effect 
on cardiovascular function in the elderly, being better toler-
ated in the same time (Messerli and Grossman 2004).
Concomitant diseases
Use of β-blockers in patients with hypertension is speciﬁ  cally 
recommended in the presence of concomitant coronary dis-
ease, particularly after myocardial infarction, congestive heart 
failure, or tachyarrythmias (Chobanian et al 2003; Mancia 
et al 2007). If a β-blocker is chosen, the agents that are more 
cardioselective offer the likelihood of fewer perturbations of 
lipid and carbohydrate metabolism and greater adherence of 
patients to therapy; only one dose a day is needed, and side 
effects are probably minimized (Kaplan 2005b).
When β-blockers are used for the treatment of hyperten-
sion, the blockade of β-adrenergic receptors may worsen 
certain concomitant diseases, such as peripheral vascular 
disease, chronic obstructive pulmonary disease, diabetes, 
depression and sexual dysfunction (Kaplan 2005b). Although 
none of these comorbid conditions is an absolute contrain-
dication to pharmacologic β-blockade, they are prone to 
decrease the patient’s tolerability for β-blockers (Messerli 
and Grossman 2004). The most common side-effect of 
β-blockade is fatigue, probably a consequence of decreased 
cardiac output and peripheral and cerebral blood ﬂ  ow (Kaplan 
2005b). Whereas negative effects of carvedilol on broncho-
spasm and depression are unlikely to be different from older 
β-blockers, the a1-blocking effects of carvedilol have been 
shown to be beneﬁ  cial in patients with diabetes (Saraﬁ  dis and 
Bakris 2006b), as discussed above and peripheral vascular 
disease (Messerli and Grossman 2004).
Concerning sexual dysfunction Fogari et al ( 2001) com-
pared the effect of carvedilol and valsartan on sexual activity 
in hypertensive men who were never treated for hypertension 
and without any previous sexual disfunction and they found 
that carvedilol induces a chronic worsening of sexual activity, Vascular Health and Risk Management 2008:4(1) 28
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whereas valsartan not only does not signiﬁ  cantly worsen 
sexual activity but may even improve it; however, no double-
blind study comparing the effect of carvedilol and traditional 
β-blockers on sexual activity is currently available.
Controlled-release carvedilol
Recently, a controlled-release formulation of carvedilol 
(carvedilol CR) has been developed, allowing once-daily dos-
ing and, thus, better adherence to medication (Osterberg and 
Blaschke 2005). Carvedilol CR is also indicated in patients 
with hypertension starting at a dose of 20 mg. A recently 
published study showed that carvedilol CR once daily were 
equivalent to carvedilol twice daily in bioavailability param-
eters (maximum plasma concentrations and trough drug 
concentration) in all doses likely to be used in hypertension (20, 
40, and 80 mg). The maximum concentration of carvedilol with 
the controlled-release formulation is reached approximately 
3.5 hours later than what is seen with the immediate-release 
preparation (Tenero et al 2006) reducing the possibility of 
concentration-dependent side effects (Packer 2006).
In a recently published study, Weber et al (2006) have 
shown that once-daily administration of carvedilol CR for 
6 weeks in doses ranging from 20 to 80 mg, alone or in com-
bination with other agents, produced sustained diastolic and 
systolic BP and heart rate reduction compared with placebo 
and an important BP-lowering effect into the early morning 
hours. Another study in 122 hypertensive patients, Henderson 
et al (Henderson et al 2006) evaluated the side-effect proﬁ  le of 
patients switching from carvedilol twice daily to carvedilol CR. 
Patients assigned to the lowest dosage of carvedilol (6.25 mg 
twice daily) for 22 days were switched to the comparable low-
est dosage of carvedilol CR (20 mg once daily) for 8 days, and 
subjects assigned to the high target dosage of carvedilol (25 mg 
twice daily) for 22 days were switched to the comparable high 
dosage of carvedilol CR (80 mg once daily) for 8 days. Patients 
experienced fewer adverse events following the switch from 
the twice daily formulation to the CR formulation for either the 
lower and higher doses of carvedilol (Henderson et al 2006). 
Multicenter studies in patients with hypertension comparing 
the effect of carvedilol CR with atenolol and metoprolol on 
surrogate markers of disease are currently underway and are 
waited to expand our knowledge in the ﬁ  eld.
Conclusions
During the past years, several studies and meta-analyses have 
demonstrated a beneﬁ  cial effect of β-blockers compared with 
placebo on the surrogate end-point of BP but their effect 
on cardiovascular morbidity and mortality in patients with 
uncomplicated hypertension remains controversial (Messerli 
et al 1998). Based on two recent randomized trials (Dahlof 
et al 2002, 2005) and in a recently published meta-analysis 
(Lindholm et al 2005), demonstrating that β-blockers were 
less effective than the comparator drug at reducing major 
cardiovascular events, the British Hypertension Society 
(National Collaborating Centre for Chronic Conditions 2006) 
has recently updated the guidelines for the management of 
hypertension, recommending that in the absence of other com-
pelling indications for β-blockade, β-blockers should not be 
a preferred initial treatment for hypertension. More recently, 
the European Society of Hypertension/European Society of 
Cardiology (Mancia et al 2007) recommend that β-blockers 
should not be preferred in hypertensives with multiple 
metabolic risk factors. These conclusions and recommenda-
tions mainly derive from studies that were conducted with 
older agents, such as atenolol and metoprolol, but it is well 
documented that there is considerable pharamacokinetic and 
pharmacodynamic heterogeneity among β-blockers. Carve-
dilol, a vasodilating noncardioselective β-blocker, represents 
an opportunity to use a cardioprotective agent without the 
concerning hemodynamic and metabolic responses associ-
ated with traditional β-blocker therapy. In contrast to classic 
β-blockers, carvedilol maintains cardiac output, has a lesser 
effect on heart rate, and decreases BP mainly by decreasing 
vascular resistance. Studies comparing carvedilol with con-
ventional β-blocking agents showed that this compound has 
much better effects on glycemic control, insulin sensitivity, 
and lipid metabolism, suggesting that it could be used in 
subjects with metabolic syndrome or diabetes without the 
fear of deterioration of these parameters. Futher, the distinct 
hemodynamic and metabolic features of carvedilol could 
result in beneﬁ  cial actions in concomitant diseases, such as 
renal disease, peripheral vascular disease and others. For 
a deﬁ  nite answer on the possible beneﬁ  ts of vasodilating 
over conventional β-blockers, studies not only on these sur-
rogate parameters but also on hard cardiovascular outcomes 
are needed. With the available evidence however, it is possible 
that carvedilol could be a valuable tool in the clinicians’ hand 
in the difﬁ  cult task of hypertension management.
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